Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

Research and Innovation Action · Running

VICT3R Developing and implementing VIrtual Control groups To reducE animal use in toxicology Research

Coordinator
Universidad Pompeu Fabra, Spain
Runs
1 September 2024 to 29 February 2028
Status
Running
EU funding
€13.5m
Total cost
€27.0m
Partners
45 organisations in 13 countries
Type
Research and Innovation Action
Grant agreement
101172693

What the project is doing

In the project's own words, from its summary on CORDIS.

VICT3R, a public-private partnership running under the European Innovative Health Initiative, aims to significantly reduce the number of animals used in experimental studies performed during the nonclinical drug and chemical safety evaluation by replacing the animals of the concurrent controls groups (CCGs) with Virtual Control Groups (VCGs). These VCGs will be generated by means of state-of-the-art statistical or artificial intelligence (AI) approaches that optimally exploit the wealth of historical data from control animals accumulated over decades by pharmaceutical companies and other relevant industrial and academic sectors.

The VCG concept was conceived and prototyped during the recently finished eTRANSAFE IMI2 project for its application in the nonclinical safety assessment of the pharmaceutical industry. A preliminary evaluation of the VCG concept carried out in the eTRANSAFE project demonstrated that it is generally feasible, yet scientifically and operationally challenging and must therefore be refined before its adoption for regulatory hazard and risk assessment.

The main challenges consist of adequate data collection and curation, identification of key variables to achieve optimal matching between VCGs and CCGs, and validation of procedures including compliance with Good Laboratory Practice (GLP). These challenges will be systematically tackled in VICT3R for achieving the full development and regulatory acceptance of the VCG concept. VICT3R will collect, curate and analyse large data sets of control animals from different species to produce a large high-quality database.

The database will be made available to VICT3R partners, regulators, and policy makers with the purpose to allow maturation of the VCG concept and to prove its validity, reproducibility and robustness. While VICT3R will be primarily focused on repeated dose toxicity studies, the extension of the VCG concept to other types of studies involving animals will also be tackled. VICT3R will promote that its database and software platform is maintained and expanded long term.

Topics

Who is involved

OrganisationCityCountryRole
Universidad Pompeu FabraBarcelonaSpainCoordinator
Janssen Pharmaceutica NVBeerseBelgiumParticipant
Ucb BiopharmaBruxelles / BrusselBelgiumParticipant
Vrije Universiteit BrusselBruxelles / BrusselBelgiumParticipant
Zoetis Belgium SALouvain La NeuveBelgiumParticipant
F. Hoffmann-La Roche AGBaselSwitzerlandParticipant
Novartis Pharma AGBaselSwitzerlandParticipant
Takeda Pharmaceuticals International AGGlattparkSwitzerlandParticipant
Amgen Research (munich) GmbHMunchenGermanyParticipant
Basf SeLudwigshafen Am RheinGermanyParticipant
Bayer AktiengesellschaftLeverkusenGermanyParticipant
Boehringer Ingelheim InternationalgmbhIngelheimGermanyParticipant
Boehringer Ingelheim Pharma GmbH &co KgIngelheimGermanyAssociatedpartner
CAATevents gGmbHSolingenGermanyParticipant
Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung eVMunchenGermanyParticipant
Merck Electronics KgaaDarmstadtGermanyAssociatedpartner
Merck Healthcare KgaaDarmstadtGermanyAssociatedpartner
Merck Kommanditgesellschaft Auf AktienDarmstadtGermanyParticipant
Merck Life Science KgaaDarmstadtGermanyAssociatedpartner
Sanofi-Aventis Deutschland GmbHFrankfurt Am MainGermanyParticipant
Syncwork AktiengesellschaftDresdenGermanyParticipant
Technische Universitat DortmundDortmundGermanyParticipant
Universitat KonstanzKonstanzGermanyParticipant
Gritsystems ASValbyDenmarkParticipant
Novo Nordisk A/sBagsvaerdDenmarkParticipant
Barcelona Supercomputing Center Centro Nacional De SupercomputacionBarcelonaSpainParticipant
Medbioinformatics Solutions SLBarcelonaSpainParticipant
Synapse Research Management Partners SLMadridSpainParticipant
Orion OyjEspooFinlandParticipant
Institut Servier De Medecine TranslationnelleGif-Sur-YvetteFranceParticipant
Ipsen Innovation SASParisFranceParticipant
Deciphex LimitedMornington MeathIrelandParticipant
Phuse Cuideachta Faoi Theorainn RathaiochtaDublinIrelandParticipant
Istituto di Ricerche Biomediche Antoine Marxer RBM S.p.A.Colleretto GiacosaItalyAssociatedpartner
Incyte Biosciences Distribution B.vAmsterdamNetherlandsParticipant
Janssen Vaccines & Prevention BVLeidenNetherlandsAssociatedpartner
Organon SRLBucharestRomaniaParticipant
Astrazeneca UK LimitedCambridgeUnited KingdomParticipant
Glaxosmithkline Research & Development LimitedLondonUnited KingdomParticipant
Instem Scientific LimitedStone StaffordshireUnited KingdomParticipant
Abbvie IncNorth Chicago IlUnited StatesParticipant
Bristol-Myers Squibb Company CorpNew YorkUnited StatesParticipant
Incyte CorporationWilmingtonUnited StatesAssociatedpartner
Janssen Research & Development, LLCRaritanUnited StatesAssociatedpartner
Pfizer IncNew York CityUnited StatesParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI